RMD · Healthcare

RESMED INC

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-07

• Astral Ventilator Sales SuspensionImportance 78 · Surprise 100
  ResMed suspended new sales of its Astral ventilators after an FDA recall. The company expects no Astral ventilator sales in fiscal 2027 while it repairs existing devices. The action is expected to reduce revenue by…
• Astral FDA RecallImportance 78 · Surprise 100
  ResMed suspended new sales of Astral ventilators in fiscal 2027 following an FDA recall and field safety action. The action is expected to reduce fiscal 2027 revenue by approximately $75 million, while company…
• Capital Return ProgramImportance 66 · Surprise 40
  ResMed returned $1.0 billion to shareholders through share repurchases and dividends during fiscal 2026. The company increased its quarterly cash dividend 10% to $0.66 per share. The dividend is payable on September…
• Guidance / OutlookImportance 62 · Surprise 68
  ResMed issued fiscal 2027 guidance for 5%-7% core revenue growth and non-GAAP diluted EPS of $12.00-$12.25. The outlook is below Wall Street revenue expectations and incorporates the $75 million impact from the Astral…
• Free Cash FlowImportance 43 · Surprise 6
  ResMed generated approximately $1.6 billion of free cash flow during fiscal 2026. Strong free cash flow supported $1.0 billion of shareholder returns through repurchases and dividends. The company expects to allocate…
• Revenue Performance and MixImportance 36 · Surprise 40
  ResMed's fourth-quarter fiscal 2026 revenue increased 9% year over year to a record $1.5 billion, or 8% on a constant-currency basis. Fiscal 2026 revenue increased 10% to $5.653 billion. Growth reflected continued…
• Sleep Apnea Treatment CompetitionImportance 23 · Surprise 24
  ResMed faces potential competitive pressure from weight-loss drugs in the market for sleep apnea devices. These therapies could reduce demand for traditional sleep apnea treatment among some patients. Conversely, Apple…
• Macroeconomic Factors ImpactImportance 10 · Surprise 6
  Third-party earnings coverage identified tariff, inflation, and hospital-spending pressures as risks entering ResMed's fiscal 2026 results. Subsequent coverage cited increased inflation as a headwind alongside the…

8-K · 2026-08-06

• Acquisition / Partnership / DivestitureImportance 96 · Surprise 100
  ResMed announced an agreement to sell its MatrixCare business, with closing expected during the first quarter of fiscal 2027. ResMed completed the acquisition of Noctrix Health, a medical-device company offering FDA De…
• Capital Return ProgramImportance 75 · Surprise 64
  ResMed returned $1.0 billion to shareholders through share repurchases and dividends during fiscal 2026, an increase of more than 70% year over year. Fiscal-year share repurchases totaled $700.0 million, compared with…
• Acquisitions and DivestituresImportance 71 · Surprise 60
  ResMed announced an agreement to sell its MatrixCare business, with closing expected during the first quarter of fiscal 2027. The balance sheet classified $457.4 million of assets and $41.2 million of liabilities as…
• Income Tax Rate ChangesImportance 64 · Surprise 56
  Fiscal-year income taxes increased 43% to $396.1 million from $276.8 million, exceeding the materiality threshold and outpacing the 15% increase in pretax income to $1,919.4 million. The resulting fiscal-year effective…
• Geographic Market CommentaryImportance 54 · Surprise 40
  Americas Sleep and Breathing Health revenue grew 8% in the fourth quarter to $853 million. Rest of World Sleep and Breathing Health revenue increased 13% reported and 10% in constant currency to $439 million. Within…
• Operating Cash Flow TrendsImportance 52 · Surprise 30
  Fiscal-year operating cash flow increased 3% to $1,805.8 million from $1,751.6 million, while free cash flow declined 1% to $1,650.0 million from $1,661.7 million. Fourth-quarter operating cash flow declined 16% to…
• Liquidity and Debt PositionImportance 52 · Surprise 30
  Cash and cash equivalents increased to $1,469.2 million at June 30, 2026, from $1,209.5 million a year earlier. Total debt increased to $659.4 million, comprising $260.0 million of short-term debt and $399.4 million of…
• Operating Margin DriversImportance 47 · Surprise 22
  Fiscal-year GAAP income from operations increased 12% to $1,886.7 million, and GAAP operating margin expanded 70 basis points to 33.4%. Fiscal-year non-GAAP operating income increased 16% to $2,039.1 million, with…
• Operating Expense TrendsImportance 46 · Surprise 30
  Fourth-quarter research and development expense increased 22% year over year to $105.7 million, or 19% on a constant-currency basis, while fiscal-year R&D expense increased 14% to $378.3 million. Fourth-quarter GAAP…
• Market Demand TrendsImportance 43 · Surprise 32
  Fourth-quarter revenue increased 9% to approximately $1.5 billion, driven by demand across sleep devices, masks, accessories, and software solutions. Global Sleep and Breathing Health revenue increased 9% to $1.292…
• Gross Margin DriversImportance 39 · Surprise 50
  Fourth-quarter GAAP gross margin declined 200 basis points to 58.8% from 60.8%, primarily because of $41.885 million in Astral field safety notification expenses. Fourth-quarter non-GAAP gross margin increased 90 basis…
• Revenue Performance and MixImportance 36 · Surprise 14
  Fourth-quarter revenue increased 9% year over year to $1,464 million, or 8% on a constant-currency basis, while fiscal-year revenue increased 10% to $5,653 million, or 8% constant currency. Fourth-quarter Sleep and…
• Product Launch and TransitionImportance 31 · Surprise 42
  ResMed launched AirSense 11 in Taiwan following launches in APAC, EMEA, and the Americas. The company also launched AirCurve 11 ST/ST-A in the United States. AirTouch F30i Comfort was launched in Brazil and Chile.…
• FX / Currency ImpactImportance 31 · Surprise 32
  ResMed reported FY2026 revenue growth of 10% to $5.653 billion, compared with 8% growth on a constant-currency basis. In the fourth quarter, revenue increased 9% to $1.464 billion, or 8% on a constant-currency basis.…
• Acquisitions and PartnershipsImportance 31 · Surprise 42
  ResMed partnered with ŌURA to expand access to sleep-health education and pathways to care. The initiative is intended to connect more people with sleep-related information and care options. The release does not…
• Strategic Digital Health ExpansionImportance 31 · Surprise 42
  As ResMed entered fiscal 2027, management said it would leverage its global scale and enhance digital capabilities. The stated strategic objectives are to improve patient outcomes, reduce healthcare costs, and drive…
• Quarterly Dividend DeclarationImportance 30 · Surprise 14
  ResMed’s board declared a quarterly cash dividend of $0.66 per share, representing a 10% increase over the previous quarterly dividend. The dividend has an August 20, 2026 record date and is payable on September 24,…

News · 2026-08-06

• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  ResMed sold its MatrixCare business for $490 million and acquired Noctrix Health for $340 million. The transactions represent a strategic portfolio shift away from the divested residential-care software asset and…
• Capital Return ProgramImportance 66 · Surprise 40
  ResMed returned $1.0 billion to shareholders through share repurchases and dividends during fiscal 2026. The company increased its quarterly cash dividend 10% to $0.66 per share. The dividend is payable on September…
• Gross Margin DriversImportance 46 · Surprise 42
  ResMed's fiscal 2026 GAAP gross margin declined slightly because of expenses associated with an Astral field safety notification. The safety action required resources to repair existing ventilators and suspend new…
• Revenue Performance and MixImportance 36 · Surprise 40
  ResMed's fourth-quarter fiscal 2026 revenue increased 9% year over year to a record $1.5 billion, or 8% on a constant-currency basis. Fiscal 2026 revenue increased 10% to $5.653 billion. Growth reflected continued…
• Home-Based Therapy AdoptionImportance 16 · Surprise 6
  ResMed’s future growth is tied to increased adoption of home-based therapy solutions. The company continues to rely on innovation in sleep and breathing health devices and software to support this transition.…